(Q48035556)

English

A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.

scientific article published in March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

phase II clinical trial

0 references

cervix uterine cancer

1 reference

based on heuristic

inferred from title

Eastern Cooperative Oncology Group

10

object named as

Eastern Cooperative Oncology Group

1 reference

Europe PubMed Central

7 February 2018

7

object named as

Robert Burk

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

author name string

Scott Wadler

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Donna Levy

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Helen L Frederickson

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Carla I Falkson

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Yuexian Wang

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Edie Weller

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Gloria Ho

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Anna S Kadish

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Gynecologic Oncology

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

92

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

957-964

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

Cancer of the Uterine Cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Recent Progress in Defining the Epidemiology of Human Papillomavirus Infection and Cervical Neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Lack of efficacy of interferon-alpha therapy in recurrent, advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Antitumor activity of interleukin 12 in preclinical models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

based on heuristic

inferred from DOI database lookup

The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2003.12.022

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/14984966

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48035556&oldid=2043390055"